EP0217572B1 - Improving carcass quality - Google Patents

Improving carcass quality Download PDF

Info

Publication number
EP0217572B1
EP0217572B1 EP86306992A EP86306992A EP0217572B1 EP 0217572 B1 EP0217572 B1 EP 0217572B1 EP 86306992 A EP86306992 A EP 86306992A EP 86306992 A EP86306992 A EP 86306992A EP 0217572 B1 EP0217572 B1 EP 0217572B1
Authority
EP
European Patent Office
Prior art keywords
animal
liveweight
day
dose rate
male
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP86306992A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0217572A3 (en
EP0217572A2 (en
Inventor
Malcolm Roy Brandon
Ian James Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Cross Biotech Pty Ltd
Original Assignee
FIDELITY FOOD TECHNOLOGIES PTY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FIDELITY FOOD TECHNOLOGIES PTY Ltd filed Critical FIDELITY FOOD TECHNOLOGIES PTY Ltd
Priority to AT86306992T priority Critical patent/ATE80040T1/de
Publication of EP0217572A2 publication Critical patent/EP0217572A2/en
Publication of EP0217572A3 publication Critical patent/EP0217572A3/en
Application granted granted Critical
Publication of EP0217572B1 publication Critical patent/EP0217572B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines

Definitions

  • a recombinant growth hormone is preferred.
  • a recombinant growth hormone selected from methionyl AA1-190 and AA4-190 has been found to be suitable for pigs.
  • GH growth hormone
  • the administration is initiated at a liveweight of 50 to 100 kg.
  • Results are essentially similar in terms of carcass quality if GH is given when the pigs initially weigh 50 to 60 kg to those found when treatment is given over a longer period, for example from 35 kg. Surprisingly, it is not necessary to increase the dose rate of GH in order to attain the same improvement in carcass quality over the shorter period. However, an improvement in feed efficiency is more apparent in treated animals over the 35 to 60 kg range.
  • the administration is initiated at a liveweight of 25 to 35 kg.
  • the improvement in carcass quality is essentially similar to that achieved over the longer period.
  • a greater relative improvement in feed conversion efficiency is noted.
  • the dose rate when the animal is a female pig, the dose rate is 0.06 to 0.1 mg/kg liveweight/day and the treatment continues for approximately 20 days prior to slaughter, when the animal is an entire male pig, the dose rate is 0.1 to 0.15 mg/kg liveweight/day and the treatment continues for approximately 20 days prior to slaughter, and, when the animal is a castrated male pig, the dose rate is 0.06 to 0.1 mg/kg liveweight/day and the treatment continues for approximately 10 days to at least about 20 days prior to slaughter;
  • the dose rate is 0.06 to 0.10 mg/kg liveweight/day and the treatment continues for 25 days prior to slaughter
  • the dose rate is 0.10 to 0.15 mg/kg liveweight/day and the treatment continues for 25 days prior to slaughter
  • the dose rate is 0.06 to 0.10 mg/kg bodyweight/day and the treatment continues for 25 days prior to slaughter
  • the dose rate when the animal is a female sheep, the dose rate is 0.06 to less than 0.10 mg/kg liveweight/day and the treatment continues for 25 days prior to slaughter, when the animal is an entire male sheep, the dose rate is 0.10 to 0.15 mg/kg liveweight/day and the treatment continues for 25 days prior to slaughter; and, when the animal is a castrated male sheep, the dose rate is 0.06 to 0.10 mg/kg liveweight/day and the treatment continues for 25 days prior to slaughter.
  • the treatment is continued for at least about 20 days prior to slaughter.
  • the treatment is administered in a slow release form, for example in the form of implantable pellets or injectable pellets.
  • a veterinary composition including an aqueous buffer solution of 3.3 to 6.6 mg/ml of a source of growth hormone selected from exogenous, homologous growth hormone, analogues, derivatives or salts thereof.
  • porcine GH, bovine GH and ovine GH prepared from fresh pituitaries by the method of Ellis (Endocrinology (1961) 69 554) was dissolved in buffer containing 0.05 M Na 2 C0 3 and 0.05 M NaHC0 3 , pH 10 to 11, and administered daily by intramuscular injection.
  • Control animals received intramuscular injections of the same buffer containing 1% lactose.
  • the pigs were fed ad libitum on a standard high energy diet supplying 14.3 MJ/kg.
  • Sheep and cattle were fed ad libitum a commerical concentrate diet. Treatment commenced when the animals were approximately the weight stated in each case, and continued until they attained their slaughter weight. The animals were deprived of food and water for 24 hours before slaughter to enable an empty liveweight to be measured.
  • the improvement in carcass parameters is the same for treatment given only over the 60 to 90 kg range as it is if given over the whole 35 to 90 kg range (Dose of GH 0.066 mg/kg/day).
  • Table 10 illustrates that in castrate males, feed conversion efficiency and growth rate are best when animals are treated over the 50 to 90 kg treatment range.
  • Fat reduction as indicated by P2 backfat is effectively achieved at a dose rate of 0.066 and is only required over the last 10 kg of growth or over approximately the last 10 days prior to slaughter.
  • Tables 11 and 12 illustrate the anabolic effect of treatment with growth hormone on carcass quality whereby the weight of dissectable lean tissue is observed.
  • Tables 13 and 14 illustrate the effectivenss of the fat reducing effect of growth hormone at higher treatment initiation weights.
  • Tables 15 to 18 illustrate that in cattle a treatment period of 50 days is to be preferred to obtain the best improvement in growth rate and feed conversion efficiency. However a greater relative improvement is achieved over the 25 day period.
  • Tables 19 to 24 illustrate that in sheep a treatment period of 50 days is to be preferred to maximise carcass quality and growth rate.
  • a dose rate of 0.132 mg/kg provides the best carcass quality and growth rate improvement but the best relative improvement for female and male castrate sheep is achieved at the lower dose rate. However, the greater relative improvement is achieved over the 25 day period.
  • Table 25 illustrates the variation in the amount of wool obtained from sheep treated with GH over 25-50 days. It may be postulated that the improvement in lean tissue content may be in an inverse relation to the reduction in wool yield. This may constitute a redirection of dietary nutrients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Springs (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Feeding And Watering For Cattle Raising And Animal Husbandry (AREA)
  • Catching Or Destruction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Paper (AREA)
  • Developing Agents For Electrophotography (AREA)
EP86306992A 1985-09-10 1986-09-10 Improving carcass quality Expired - Lifetime EP0217572B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT86306992T ATE80040T1 (de) 1985-09-10 1986-09-10 Verbesserung der koerperqualitaet.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPH235685 1985-09-10
AU2356/85 1985-09-10
AU62522/86A AU599922B2 (en) 1985-09-10 1986-09-09 Improving carcass quality

Publications (3)

Publication Number Publication Date
EP0217572A2 EP0217572A2 (en) 1987-04-08
EP0217572A3 EP0217572A3 (en) 1988-06-29
EP0217572B1 true EP0217572B1 (en) 1992-09-02

Family

ID=3771267

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86306992A Expired - Lifetime EP0217572B1 (en) 1985-09-10 1986-09-10 Improving carcass quality

Country Status (8)

Country Link
EP (1) EP0217572B1 (da)
JP (1) JPS62130633A (da)
AT (1) ATE80040T1 (da)
AU (1) AU599922B2 (da)
CA (1) CA1319609C (da)
DE (1) DE3686625T2 (da)
DK (1) DK171390B1 (da)
NZ (1) NZ217525A (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279616A3 (en) * 1987-02-17 1990-03-07 International Minerals And Chemical Corporation Swine growth promotion
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5637566A (en) * 1988-08-24 1997-06-10 Southern Cross Biotech Pty. Ltd. Method of improving carcass quality by administering growth hormone
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
AU647374B2 (en) * 1988-09-29 1994-03-24 Natinco Nv Sheep growth hormone
DK472189A (da) * 1988-09-29 1990-03-30 Bunge Australia Vaeksthormon
CN102132683A (zh) * 2010-01-22 2011-07-27 张黎华 猪、牛、羊的饲养、屠宰及食用新方法
CN105961334A (zh) * 2016-06-06 2016-09-28 天津市宁河原种猪场 根据背膘定量饲喂母猪的管理方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0085036A1 (en) * 1982-01-18 1983-08-03 Monsanto Company Method for improved bovine milk production
EP0103395A3 (en) * 1982-08-17 1985-05-22 Biogen N.V. Dna sequences, recombinant dna molecules and processes for producing bovine growth hormone-like polypeptides in high yield
AU579989B2 (en) * 1982-09-28 1988-12-22 Sds Biotech K.K. Somatomedin growth promoter
PT79094B (en) * 1983-08-29 1986-08-14 Salk Inst For Biological Studi Grf analogs
US4818531A (en) * 1985-02-06 1989-04-04 Eli Lilly And Company Growth hormone and thyroid hormone
US5037806A (en) * 1985-02-22 1991-08-06 Monsanto Company Biologically active method using somatotropins
US4670249A (en) * 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions

Also Published As

Publication number Publication date
AU6252286A (en) 1987-03-12
DE3686625D1 (de) 1992-10-08
CA1319609C (en) 1993-06-29
DE3686625T2 (de) 1993-01-28
EP0217572A3 (en) 1988-06-29
DK431486A (da) 1987-03-11
JPS62130633A (ja) 1987-06-12
NZ217525A (en) 1989-09-27
DK431486D0 (da) 1986-09-10
AU599922B2 (en) 1990-08-02
ATE80040T1 (de) 1992-09-15
EP0217572A2 (en) 1987-04-08
DK171390B1 (da) 1996-10-14

Similar Documents

Publication Publication Date Title
Bauman et al. Responses of high-producing dairy cows to long-term treatment with pituitary somatotropin and recombinant somatotropin
US4818531A (en) Growth hormone and thyroid hormone
US5087472A (en) Feed compositions for domestics animals containing hydroxymethylbutyrate
WO1991011111A1 (en) Method of raising meat producing animals to increase lean tissue development
EP0217572B1 (en) Improving carcass quality
KR100513420B1 (ko) 반추동물의 비육방법
US5004728A (en) Methods of increasing milk yields in ruminants
US4792546A (en) Method for increasing weight gains and reducing deposition of fat in animals
Spencer et al. Effect of recombinant human insulin-like growth factor-II on weight gain and body composition of broiler chickens
Schneider et al. Responses of dairy cows in early lactation to bovine somatotropin and ruminally inert fat
US5686413A (en) Ractopamine and growth hormone combinations
RU2160531C1 (ru) Способ кормления свиней
EP0362999B1 (en) Improved carcass quality
Chilliard Physiological constraints to milk production: factors which determine nutrient partitioning, lactation persistency and mobilization of body reserves
US5637566A (en) Method of improving carcass quality by administering growth hormone
EP0333349B1 (en) Phenethanolamine and growth hormone combinations
US5162302A (en) Endocrine manipulation to improve body composition of poultry
Wray-Cahen Performance-enhancing substances
CN108935991A (zh) 一种肉牛育肥后期用饲料
Chalupa et al. Bovine somatotropin: physiology, lactational responses and implications for the dairy industry
US3737535A (en) Method of fattening beef cattle
US5168102A (en) Endocrine manipulation to improve body composition of poultry
Eisenbeisz Lactational evaluation of recombinant bovine somatotropin with corn and barley diets
Sainz et al. Exogenous growth hormone releasing factors and cottonseed meal improve growth performance and composition of gain in lambs fed lucerne chaff ad libitum
SU755262A1 (ru) Способ повышения мясностй свиней 1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19880812

17Q First examination report despatched

Effective date: 19900730

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FIDELITY FOOD TECHNOLOGIES PTY. LTD.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19920819

Year of fee payment: 7

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 80040

Country of ref document: AT

Date of ref document: 19920915

Kind code of ref document: T

ITF It: translation for a ep patent filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19920928

Year of fee payment: 7

REF Corresponds to:

Ref document number: 3686625

Country of ref document: DE

Date of ref document: 19921008

ET Fr: translation filed
EPTA Lu: last paid annual fee
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19930910

ITTA It: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19930930

Ref country code: CH

Effective date: 19930930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

EAL Se: european patent in force in sweden

Ref document number: 86306992.8

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

NLS Nl: assignments of ep-patents

Owner name: SOUTHERN CROSS BIOTECH PTY. LTD.

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

NLS Nl: assignments of ep-patents

Owner name: NATINCO N.V.

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

BECA Be: change of holder's address

Free format text: 20000530 *NATINCO N.V.:PLAZA JOJO, CORREA 1-5 WILLEMSTED CURACAO

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050823

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20050904

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20050906

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050907

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050909

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20050913

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20050927

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20051121

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20060909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20060910

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20060910

EUG Se: european patent has lapsed
BE20 Be: patent expired

Owner name: *NATINCO N.V.

Effective date: 20060910